For 42-year-old Hannu Rajaniemi, the decision to shift his synthetic biology start-up's focus from creating cancer therapeutics to making a Covid-19 vaccine brought a sense of calm.
So from March 10 through March 16, Rajaniemi pivoted his Cambridge, Massachusetts-headquartered business,, from working to build a cancer vaccine to inventing a vaccine against SARS-CoV-2, the virus that causes Covid-19. technology forward rapidly while fighting the pandemic, then bring it back to cancer," he said. According to Rajaniemi, one investor said the Covid-19 pandemic "could be THE opportunity you needed" to show what the team can really accomplish.
And it is "quite empowering" to be working on something that could help the world, Rajaniemi says. "There is this strong sense of clarity.... This is what we have to focus on. And so I think that's actually made it easier."Rajaniemi, who was born and raised in Finland, founded Helix Nanotechnologies in 2013 with small angel checks from friends and family as well as grants to focus on cancer therapeutics.
The work centered around manipulating messenger ribonucleic acid , or genetic code that acts as a messenger in the human body. Helix Nanotechnology's strategy for generating a novel coronavirus vaccine also centers on mRNA.
MakeIt shourya3551 Meenakshinn SharrmaAbhishek ManojSi86258258
MakeIt Y'all getting all that money for a vaccine that absolutely nobody is gonna get
MakeIt